| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/9780470975114.CH12 |
| P50 | author | Eduard Vieta | Q20090640 |
| P2093 | author name string | Alessandra Nivoli | |
| P2860 | cites work | No influence of FAT polymorphisms in response to aripiprazole | Q43247461 |
| Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. | Q43286876 | ||
| Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors | Q44028935 | ||
| Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study | Q44159999 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats | Q44675329 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. | Q45484599 | ||
| Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. | Q46012086 | ||
| Influence of TAAR6 polymorphisms on response to aripiprazole | Q46061595 | ||
| Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients | Q46064788 | ||
| A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder | Q46170156 | ||
| Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study | Q46178044 | ||
| The long-term natural history of the weekly symptomatic status of bipolar I disorder | Q46317822 | ||
| Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole | Q46373013 | ||
| Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study | Q46669710 | ||
| Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial | Q46681464 | ||
| Change in sexual dysfunction with aripiprazole: a switching or add-on study | Q46727015 | ||
| Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies | Q46801835 | ||
| Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study | Q46886132 | ||
| Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial | Q46952830 | ||
| Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder | Q46975571 | ||
| Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole | Q48472617 | ||
| Adjunctive aripiprazole in treatment-resistant bipolar depression. | Q51789886 | ||
| Haloperidol alone or in combination for acute mania | Q24245158 | ||
| Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes | Q28375923 | ||
| Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study | Q33186211 | ||
| The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor | Q33959664 | ||
| Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review | Q33988376 | ||
| Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain | Q34326136 | ||
| Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. | Q34375654 | ||
| Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). | Q34564599 | ||
| Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies | Q34605085 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania | Q34606256 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression | Q34616633 | ||
| Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study | Q34655996 | ||
| Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients | Q35985928 | ||
| The crossover approach to switching antipsychotics: what is the evidence? | Q36159323 | ||
| Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy | Q36687342 | ||
| Abnormal glucose metabolism in patients treated with antipsychotics | Q36782498 | ||
| Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials | Q36936379 | ||
| Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review | Q37299210 | ||
| A UK consensus on the administration of aripiprazole for the treatment of mania | Q37326130 | ||
| Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology | Q37426143 | ||
| Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study | Q38377712 | ||
| Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial | Q38382241 | ||
| Genetic association between 5'-upstream single-nucleotide polymorphisms of PDGFRB and schizophrenia in a Korean population | Q40082891 | ||
| Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole | Q41528294 | ||
| Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial | Q42609214 | ||
| A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression | Q42645277 | ||
| A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). | Q42930552 | ||
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 245-269 | |
| P577 | publication date | 2011-04-13 | |
| P1476 | title | Aripiprazole in Bipolar Disorder |
Search more.